PMID- 17001352
OWN - NLM
STAT- MEDLINE
DCOM- 20071101
LR  - 20221207
IS  - 1470-269X (Print)
IS  - 1470-269X (Linking)
VI  - 7
IP  - 5
DP  - 2007 Oct
TI  - Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues 
      for associations with human leukocyte class I and II antigens.
PG  - 325-32
AB  - Clozapine-induced agranulocytosis (CA) is still among the least understood 
      adverse drug reactions in psychopharmacology. In particular, its genetic 
      background is far from being clarified. Within the framework of a case-control 
      study, we performed human leukocyte antigen (HLA) genotyping and haplotype 
      analyses in 42 non-Jewish Caucasian schizophrenic patients (N=42) suffering from 
      CA and 75 non-Jewish Caucasian schizophrenic patients treated with clozapine 
      without developing CA. While controlling for age (P<0.0001) and sex (P=0.835), 
      testing of the alleles from both HLA-loci resulted in borderline results for Cw2 
      (P=0.085, odds ratio (OR)=0.36, 95% confidence interval (CI): 0.08-1.23), Cw7 
      (P=0.058, OR=2.0, 95% CI: 0.87-4.63) and DRB5*0201 (P=0.005, adjusted OR=22.15). 
      For haplotype analysis, we obtained significant association results with CA for 
      the two-locus haplotypes HLA-Cw-B (P=0.022) and HLA-DRB5-DRB4 (P=0.050), and for 
      the three-locus haplotype HLA-Cw-B-DRB5 (P=0.030). The complex nature of CA 
      implies that many genes might play a role, but currently, only HLA associations 
      with CA are identified as clinically relevant.
FAU - Dettling, M
AU  - Dettling M
AD  - Department of Psychiatry and Psychotherapy, Charite-University Medicine Berlin, 
      Berlin, Germany. michael.dettling@charite.de
FAU - Cascorbi, I
AU  - Cascorbi I
FAU - Opgen-Rhein, C
AU  - Opgen-Rhein C
FAU - Schaub, R
AU  - Schaub R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20061017
PL  - United States
TA  - Pharmacogenomics J
JT  - The pharmacogenomics journal
JID - 101083949
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - J60AR2IKIC (Clozapine)
SB  - IM
MH  - Adult
MH  - Agranulocytosis/chemically induced/*genetics/immunology
MH  - Antipsychotic Agents/*adverse effects
MH  - Case-Control Studies
MH  - Clozapine/*adverse effects
MH  - Female
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease
MH  - Haplotypes
MH  - Histocompatibility Antigens Class I/*genetics
MH  - Histocompatibility Antigens Class II/*genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Risk Assessment
MH  - Risk Factors
MH  - Schizophrenia/*drug therapy/genetics/immunology
MH  - Treatment Outcome
MH  - White People/*genetics
EDAT- 2006/09/27 09:00
MHDA- 2007/11/02 09:00
CRDT- 2006/09/27 09:00
PHST- 2006/09/27 09:00 [pubmed]
PHST- 2007/11/02 09:00 [medline]
PHST- 2006/09/27 09:00 [entrez]
AID - 6500423 [pii]
AID - 10.1038/sj.tpj.6500423 [doi]
PST - ppublish
SO  - Pharmacogenomics J. 2007 Oct;7(5):325-32. doi: 10.1038/sj.tpj.6500423. Epub 2006 
      Oct 17.